Many consumers mistakenly believe new prescription drugs are always safer than those with long track records, and that only extremely effective drugs without major side effects win government approval, according to a new ...
Sep 12, 2011
0
0
A quarter-century after the U.S. Food and Drug Administration approved the first prescription drugs based on the main psychoactive ingredient in marijuana, additional medicines derived from or inspired by the cannabis plant ...
Jan 23, 2012
0
0
(HealthDay)—The U.S. Food and Drug Administration has approved a new treatment for acne scarring.
Jan 8, 2015
0
10
(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among patients with rheumatoid arthritis ...
Mar 1, 2019
0
5
A new digital headset designed to measure alterations in brain function could change decisions about how quickly an athlete is ready to return to play after a concussion. In an evaluation of the device, UC San Francisco researchers ...
Aug 12, 2023
0
46
To win the battle against heart disease, cardiologists need better ways to identify the composition of plaque most likely to rupture and cause a heart attack. Angiography allows them to examine blood vessels for constricted ...
Oct 3, 2017
0
42
Colchicine, a widely available gout medication, has received FDA approval to be used in low dose to prevent cardiovascular events in patients with proven coronary disease.
Jun 29, 2023
0
32
The rugged, low-cost wheelchairs designed by SF State's Whirlwind Wheelchair program have helped thousands of people in developing countries. Now they're available in the U.S., where they are opening up new territory for ...
Dec 14, 2012
0
1
When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for ...
Sep 23, 2015
0
11
(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.
Dec 7, 2011
0
0
